Tirzepatide/Mounjaro®, a novel GLP-1R/GIPR dual agonist, was recently approved by the FDA for T2DM treatment, and demonstrated enhanced insulinotropic benefits relative to single GLP-1R agonists in clinical trials [48]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.